Clinical Report: The Evolving Treatment Landscape for Wet AMD
Overview
Recent studies highlight the sustained efficacy and safety of Vabysmo and Eylea HD in treating wet AMD, with promising data from extension studies showing maintained visual acuity and central subfield thickness improvements. New investigational agents also show potential for enhanced treatment durability.
Background
Wet age-related macular degeneration (AMD) is a leading cause of vision loss in older adults, making effective treatment crucial for preserving sight. The introduction of anti-VEGF therapies has transformed management strategies, but ongoing research is essential to improve treatment durability and patient outcomes. Recent advancements in drug formulations and delivery systems are paving the way for more effective long-term management of this condition.
Data Highlights
| Study | Findings |
|---|---|
| AVONELLE-X (Vabysmo) | 4-year data shows maintained BCVA and CST improvements |
| PULSAR (Eylea HD) | 3-year data indicates stable visual acuity and CST reductions |
| PORTAL (Susvimo) | 5-year data confirms durability and maintained BCVA after switching to port delivery system |
Key Findings
- Vabysmo and Eylea HD show sustained efficacy in pivotal extension studies.
- BCVA and CST improvements remain stable over extended treatment periods.
- Susvimo offers a continuous delivery alternative with maintained visual outcomes.
- New anti-VEGF agents like TH-103 demonstrate enhanced binding and durability.
- Gene therapy and TKIs are emerging as promising treatment options.
Clinical Implications
The findings underscore the importance of individualized treatment plans that consider both efficacy and patient burden. Clinicians should stay informed about new therapies and extension study results to optimize management strategies for wet AMD.
Conclusion
The evolving treatment landscape for wet AMD offers hope for improved patient outcomes through sustained efficacy and innovative therapies. Ongoing research will continue to shape the future of AMD management.
References
- American Academy of Ophthalmology, AAO Preferred Practice Pattern, 2025 -- Age-Related Macular Degeneration
- Roche, Investor Update, 2025 -- New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration
- Retinal Physician, April 2022 -- Treating AMD at the Intermediate Level
- Retinal Physician, April 2022 -- Early-phase Drugs in Development for Dry AMD
- Retinal Physician, May 2025 -- Clinical Trial Update
- Contact Lens Spectrum — treatment plan
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD)
- Comparative efficacy and safety of faricimab, aflibercept, conbercept, and ranibizumab for neovascular age-related macular degeneration: A systematic review and network meta-analysis - PubMed
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
